SCHEMBL5201667

SCHEMBL5201667

CC(C)[C@H](NC(=O)OC(C)(C)C)C(=O)N1C[C@@H](F)C[C@H]1C#N

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 18/20 0.50
FAP Q12884 5/20 0.50
CTSK P43235 2/20 0.50
CTSL P07711 1/20 0.50
CTSB P07858 1/20 0.50
CTSS P25774 1/20 0.45
DPP7 Q9UHL4 4/20 0.44
DPP8 Q6V1X1 3/20 0.44
DPP9 Q86TI2 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202268 0.90 DPP4 (0.48) DPP4FAPDPP7DPP8DPP9
SCHEMBL5202988 0.89 DPP4 (0.59) DPP4FAPCTSKCTSLCTSB
SCHEMBL5201959 0.89 DPP4 (0.59) DPP4FAPCTSKCTSLCTSB
SCHEMBL5202254 0.87 DPP4 (0.51) DPP4FAPDPP7DPP8DPP9
SCHEMBL8304076 0.83 DPP4 (0.61) DPP4FAPDPP7DPP8DPP9
SCHEMBL3170213 0.83 DPP4 (0.61) DPP4FAPDPP7DPP8DPP9
SCHEMBL8316490 0.81 CTSK (0.55) CTSKCTSLCTSBCTSS
SCHEMBL5206543 0.81 DPP4 (0.52) DPP4FAPDPP7DPP8DPP9
SCHEMBL5203233 0.81 PIN1 (0.54) CTSKCTSLCTSBCTSS
SCHEMBL31528781 0.80 DPP4 (0.47) DPP4FAPDPP7DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070112059-A1 CYANOPYRROLIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. 2007-05-17 US disclosed
US-20070112205-A1 CYANOPYRROLIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. 2007-05-17 US disclosed
EP-1746086-A1 Cyanopyrrolidine derivatives TAISHO PHARMACEUTICAL CO., LTD (JP) 2007-01-24 EP disclosed
US-20040072892-A1 Cyanopyrrolidine derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 US disclosed
EP-1333025-A1 CYANOPYRROLIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2003-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072892-A1 Cyanopyrrolidine derivatives CCR9, OPRD1, CBR1 DPP4 2412/4885FAP 3334/4885CTSK 3996/4885
US-20070112059-A1 CYANOPYRROLIDINE DERIVATIVES DPP4, DPP9, DPP3 DPP4 1/4885FAP 40/4885CTSK 512/4885
US-20070112205-A1 CYANOPYRROLIDINE DERIVATIVES CBR3, CBR1, TERT DPP4 3721/4885FAP 2348/4885CTSK 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.